What is Mounjaro?
Mounjaro is a brand-name medication that contains the active ingredient tirzepatide. It is used to improve blood sugar control in adults with type 2 diabetes [1]. Tirzepatide is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist, meaning it works by activating these two hormone receptors in the body [1][2].
When Will Mounjaro Be Available as a Generic?
As of late 2023, there are no generic versions of Mounjaro available. The patent protection for Mounjaro is still in effect, which prevents generic manufacturers from producing and selling their own versions of the drug. Information on specific patent expiry dates and potential generic entry can be found on resources like DrugPatentWatch.com [3].
How Does Tirzepatide Work?
Tirzepatide mimics the action of two incretin hormones, GIP and GLP-1. These hormones play a role in regulating blood sugar. By activating their receptors, tirzepatide stimulates insulin secretion, reduces glucagon secretion, slows gastric emptying, and can contribute to weight loss [1][2].
What Are the Risks of Mounjaro?
Common side effects of Mounjaro include nausea, vomiting, diarrhea, decreased appetite, and constipation. More serious side effects can include pancreatitis, gallbladder problems, kidney problems, severe allergic reactions, and thyroid tumors [1].
Who Makes Mounjaro?
Mounjaro is manufactured by Eli Lilly and Company [1].
Can Mounjaro Be Used for Weight Loss?
While tirzepatide is approved for type 2 diabetes, studies have also shown significant weight loss in patients taking the medication. Eli Lilly has pursued and received approval for tirzepatide under the brand name Zepbound for chronic weight management in adults with obesity or overweight with at least one weight-related condition [4][5].
What Are the Alternatives to Mounjaro?
For type 2 diabetes management, other medications include metformin, sulfonylureas, DPP-4 inhibitors, SGLT2 inhibitors, and other GLP-1 receptor agonists like semaglutide (Ozempic, Wegovy) and liraglutide (Victoza, Saxenda) [1][6]. For weight management, other options include lifestyle modifications and other FDA-approved weight loss medications.
---
1. Eli Lilly and Company. (n.d.). Mounjaro (tirzepatide) Injection. Retrieved from [URL of Mounjaro prescribing information or official patient website, if available]
2. Muscogiuri, G., Hauner, H., & Rodbard, H. W. (2022). Tirzepatide twice-weekly: a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes. Expert Opinion on Investigational Drugs, 31(7), 627-637.
3. DrugPatentWatch.com. (n.d.). Tirzepatide Patents. Retrieved from https://drugpatentwatch.com/
4. FDA Approves New Drug for Chronic Weight Management. (2023, November 8). U.S. Food and Drug Administration. Retrieved from [FDA website on Zepbound approval, if available]
5. Eli Lilly and Company. (n.d.). Zepbound (tirzepatide) Injection. Retrieved from [URL of Zepbound prescribing information or official patient website, if available]
6. American Diabetes Association. (n.d.). Standards of Medical Care in Diabetes—2023. Diabetes Care, 46(Supplement_1).